TY -的T1 -肺< em >分枝杆菌脓肿us: can we identify the road to improved outcomes? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01121-2019 VL - 54 IS - 1 SP - 1901121 AU - Connell, David W. AU - Wilkie, Morven Y1 - 2019/07/01 UR - //www.qdcxjkg.com/content/54/1/1901121.abstract N2 - Despite much welcome progress over the past decade in the field of chronic respiratory infections and bronchiectasis [1], treatment of pulmonary disease caused by infections with nontuberculous mycobacteria (NTM-PD) remains an area of significant, and increasing, challenge [2, 3]. Pulmonary disease caused by Mycobacterium abscessus (MAB-PD) is of particular interest as, when coupled with underlying lung disease, it is associated with rapidly declining lung function, significant morbidity and mortality, and particularly poor treatment outcomes: cure, as generally defined by persistent culture conversion, is generally reported to be found in less than 50% of cases in published data [4, 5]. The challenge is amplified by the fact that the incidence of MAB-PD may also be increasing [6], possibly as a result of ageing populations with pre-existing lung disease, alongside increasing use of immunosuppressant drugs, and increased environmental exposure.The findings of this meta-analysis suggest that specific targeted therapy for Mycobacterium abscessus subspecies abscessus can improve treatment outcomes, and may help to design future antimicrobial drug regimens in this difficult to treat lung infection http://bit.ly/2WOFsRw ER -